Ablative Therapies for Breast Cancer: State of Art.
Serena CarrieroCarolina LanzaGiuseppe PellegrinoVelio AscentiCaterina SattinCaterina PizziSalvatore Alessio AngileriPierpaolo BiondettiAndrea Antonio IannielloFilippo PiacentinoRoberto LavoratoAnna Maria IerardiGianpaolo CarrafielloPublished in: Technology in cancer research & treatment (2023)
Breast cancer (BC) is the most frequently diagnosed malignancy among women. In the past two decades, new technologies and BC screening have led to the diagnosis of smaller and earlier-stage BC (ESBC). Therefore, percutaneous minimally invasive techniques (PMIT) were adopted to treat patients unfit for surgery, women who refuse it, or elderly patients with comorbidities that could make surgery a difficult and life-threatening treatment. The target of PMIT is small-size ESBC with the scope of obtaining similar efficacy as surgery. Minimally invasive treatments are convenient alternatives with promising effectiveness, lower morbidity, less cost, less scarring and pain, and more satisfying cosmetic results. Ablative techniques used in BC are cryoablation, radiofrequency ablation, microwave ablation, high-intensity focused ultrasound (US), and laser ablation. The aim of our study is to discuss the current status of percutaneous management of BC, evaluate the clinical outcomes of PMIT in BC, and analyze future perspectives regarding ablation therapy in BC.
Keyphrases
- minimally invasive
- radiofrequency ablation
- high intensity
- robot assisted
- polycystic ovary syndrome
- coronary artery bypass
- end stage renal disease
- current status
- systematic review
- breast cancer risk
- newly diagnosed
- chronic pain
- peritoneal dialysis
- spinal cord injury
- stem cells
- spinal cord
- prognostic factors
- bone marrow
- pregnancy outcomes
- catheter ablation
- combination therapy
- cell therapy
- patient reported
- mass spectrometry
- percutaneous coronary intervention
- community dwelling
- replacement therapy